Abstract #1353

Translation of 2-hydroxyglutarate MR spectroscopy into clinics

Zhongxu An¹, Sandeep Ganji¹, Vivek Tiwari¹, Edward Pan^2,3,4, Bruce Mickey^2,4,5, Elizabeth A. Maher^2,3,5,6, and Changho Choi^1,2,7

¹Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, TX, United States, ²Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, United States, ³Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, United States, ⁴Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, TX, United States, ⁵Annette Strauss Center for Neuro-Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States, ⁶Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States, ⁷Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, United States

2-hydroxyglutarate (2HG) is an important biomarker for IDH-mutated gliomas. Thus in vivo measurement of 2-hydroxyglutarate can provide important information for brain tumor diagnosis and prognosis. Several techniques for in-vivo detection of 2HG were reported recently. However, due to limited access to scan parameters in clinical setup, translation of such techniques into clinics is limited. We report the reproducibility of a recently developed clinically-available PRESS-based 1H MRS method, for in vivo 2HG measurement at research and clinical scanners.

This abstract and the presentation materials are available to members only; a login is required.

Join Here